PMID- 34212530
OWN - NLM
STAT- MEDLINE
DCOM- 20220114
LR  - 20220114
IS  - 2574-173X (Electronic)
IS  - 2574-173X (Linking)
VI  - 41
IP  - 3
DP  - 2021 Sep
TI  - Outcomes of patients with schizophrenia who discontinued long-acting injectable 
      antipsychotic therapy due to adverse events: A chart review.
PG  - 422-425
LID - 10.1002/npr2.12192 [doi]
AB  - AIM: We conducted a chart review to investigate the detailed outcomes of patients 
      with schizophrenia who discontinued long-acting injectable second-generation 
      antipsychotic (LAI-SGA) therapy due to adverse events (AEs). METHODS: The study 
      included patients with schizophrenia and related psychotic disorders who 
      commenced LAI-SGA therapy between January/1//2009 and March/31/2020 at Fujita 
      Health University Hospital in Toyoake, Japan. RESULTS: We conducted a chart 
      review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 
      5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, 
      paliperidone palmitate, and risperidone-LAI groups, respectively, discontinued 
      due to AEs since the start of LAI-SGA therapy. Three patients required 
      hospitalization for AE treatment. CONCLUSION: The severity of these AEs in most 
      patients is moderate (ie, no hospital treatment required). Due to the small 
      sample size, a larger study is needed to confirm/replicate our study results.
CI  - (c) 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & 
      Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
FAU - Kishi, Taro
AU  - Kishi T
AUID- ORCID: 0000-0002-9237-2236
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Japan.
FAU - Sakuma, Kenji
AU  - Sakuma K
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Japan.
FAU - Okuya, Makoto
AU  - Okuya M
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Japan.
FAU - Hatano, Masakazu
AU  - Hatano M
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Japan.
AD  - Department of Clinical Pharmacy, Fujita Health University School of Medicine, 
      Toyoake, Japan.
FAU - Iwata, Nakao
AU  - Iwata N
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210701
PL  - United States
TA  - Neuropsychopharmacol Rep
JT  - Neuropsychopharmacology reports
JID - 101719700
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 82VFR53I78 (Aripiprazole)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - *Antipsychotic Agents/adverse effects
MH  - Aripiprazole/adverse effects
MH  - Delayed-Action Preparations/therapeutic use
MH  - Humans
MH  - Paliperidone Palmitate/adverse effects
MH  - *Schizophrenia/drug therapy
PMC - PMC8411314
OTO - NOTNLM
OT  - adverse events
OT  - long-acting injectable second-generation antipsychotic
OT  - schizophrenia
COIS- Dr Kishi, Dr Sakuma, Dr Okuya, Dr Hatano, and Dr Iwata declare that they have no 
      direct conflicts of interest relevant to this study. Dr Kishi received speaker's 
      honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, 
      Mochida, MSD, and Tanabe-Mitsubishi (Yoshitomi), as well as research grants from 
      the Japanese Ministry of Health, Labour, and Welfare, a MEXT/JSPS KAKENHI grant 
      (number 19K08082), and Fujita Health University School of Medicine. This work was 
      supported by a MEXT/JSPS KAKENHI grant (number 19K08082). This funding source had 
      no role in the design of this study and will not have any role during its 
      execution, analyses, interpretation of the data, or decision to submit results. 
      Dr Sakuma has received speaker's honoraria from Eisai, Kissei, Meiji, Otsuka, and 
      Torii and has received a Fujita Health University School of Medicine research 
      grant, as well as a MEXT/JSPS KAKENHI Grant for Young Scientists (B). Dr Okuya 
      has received speaker's honoraria from Meiji and has received a Fujita Health 
      University School of Medicine research grant, as well as a MEXT/JSPS KAKENHI 
      Grant for Young Scientists. Dr Hatano has received speaker's honoraria from 
      Dainippon Sumitomo and Otsuka. Dr Iwata has received speaker's honoraria from 
      Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, 
      Takeda, Meiji, and Pfizer, along with research grants from Daiichi Sankyo, 
      Takeda, Dainippon Sumitomo Eisai, Meiji, Tanabe-Mitsubishi, and Otsuka.
EDAT- 2021/07/03 06:00
MHDA- 2022/01/15 06:00
PMCR- 2021/07/01
CRDT- 2021/07/02 07:07
PHST- 2021/06/17 00:00 [revised]
PHST- 2021/05/17 00:00 [received]
PHST- 2021/06/18 00:00 [accepted]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2022/01/15 06:00 [medline]
PHST- 2021/07/02 07:07 [entrez]
PHST- 2021/07/01 00:00 [pmc-release]
AID - NPR212192 [pii]
AID - 10.1002/npr2.12192 [doi]
PST - ppublish
SO  - Neuropsychopharmacol Rep. 2021 Sep;41(3):422-425. doi: 10.1002/npr2.12192. Epub 
      2021 Jul 1.